PF-05089771 is a NaV1.7-selective arylsulfonamide that has undergone phase II trials for primary erthromyelgia (Cao et al., 2016) and painful diabetic neuropathy (McDonnell et al., 2018). Here, SCN9A is linked to diabetic neuropathy.